APLIF
Appili Therapeutics Inc.
Set alert
0.01 USD 0.00 0.00%
0.004 Day range 0.0068
0.004 52-week range 0.02
- YTD
- -53.33%
- 1 year
- -63.16%
- Open
- 0.004
- Prev close
- 0.007
- Mkt cap
- 926.56K
- Vol
- 36.65K
- Avg vol
- 5.43K
- EPS
- -0.03
- P/E
- 0.00
More statistics
- Low
- 0.004
- High
- 0.0068
- Earnings
- Feb 11, 2025
Next earnings
Feb 11, 2025
Expected Feb 11, 2025. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2025 | Dec 1, 2024 | 0.00 | — | — | — |
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | 0.00 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | -0.01 | — | — |
| Jun 25, 2024 | Mar 1, 2024 | -0.01 | -0.01 | 0.00 | 0.00% |
| Feb 13, 2024 | Dec 1, 2023 | -0.01 | 0.00 | — | — |
| Nov 13, 2023 | Sep 1, 2023 | -0.01 | -0.01 | 0.00 | 0.00% |
News
- Appili Therapeutics Announces Transfer to NEX
- Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2027
- Appili Therapeutics Announces Receipt from NIAID of a Notice of Termination for Convenience on the Contract for the VXV-01 Program
- Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results
- Appili Therapeutics to Exhibit at World Vaccine Congress Washington
- Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement
- Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026
- Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026
- Appili Therapeutics to Attend BARDA Innovation Symposium 2025
- Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01
Your note
Sign in to keep a note on APLIF — it syncs with the Stock Master app.